Does the media prefer AMRX or VTRS?

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 2 mentions for Viatris. Viatris' average media sentiment score of 1.15 beat Amneal Pharmaceuticals' score of 0.71 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JAZZ or AMRX?

In the previous week, Jazz Pharmaceuticals had 36 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 42 mentions for Jazz Pharmaceuticals and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.71 beat Jazz Pharmaceuticals' score of 0.35 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 11 Very Positive mention(s) 9 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or NBIX?

In the previous week, Neurocrine Biosciences had 17 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 6 mentions for Amneal Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 1.34 beat Amneal Pharmaceuticals' score of 0.71 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 20 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or CORT?

In the previous week, Corcept Therapeutics had 18 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 24 mentions for Corcept Therapeutics and 6 mentions for Amneal Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.85 beat Amneal Pharmaceuticals' score of 0.71 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 17 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or AMRX?

In the previous week, Elanco Animal Health had 8 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Elanco Animal Health and 6 mentions for Amneal Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.36 beat Amneal Pharmaceuticals' score of 0.71 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Amneal Pharmaceuticals (AMRX) Competitors

$17.54 -0.47 (-2.61%)

As of 08/28/2026 04:00 PM Eastern

Compare

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

Should you buy Amneal Pharmaceuticals stock or one of its competitors? Amneal Pharmaceuticals's main competitors and comparable companies include Viatris (VTRS), Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), and Elanco Animal Health (ELAN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Amneal Pharmaceuticals compare to Viatris?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Viatris (NASDAQ:VTRS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Viatris	-2.79%	20.02%	8.02%

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 2 mentions for Viatris. Viatris' average media sentiment score of 1.15 beat Amneal Pharmaceuticals' score of 0.71 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals presently has a consensus price target of $19.00, suggesting a potential upside of 8.32%. Viatris has a consensus price target of $17.50, suggesting a potential upside of 7.10%. Given Amneal Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Amneal Pharmaceuticals is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Amneal Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.86	$72.06M	$0.49	35.80
Viatris	$14.30B	1.31	-$3.51B	-$0.36	N/A

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amneal Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Viatris on 12 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Amneal Pharmaceuticals has lower revenue, but higher earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.27B	3.72	-$356.15M	$14.50	16.86
Amneal Pharmaceuticals	$3.02B	1.86	$72.06M	$0.49	35.80

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Amneal Pharmaceuticals' net margin of 5.05%. Jazz Pharmaceuticals' return on equity of 33.97% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Jazz Pharmaceuticals presently has a consensus price target of $285.44, indicating a potential upside of 16.73%. Amneal Pharmaceuticals has a consensus price target of $19.00, indicating a potential upside of 8.32%. Given Jazz Pharmaceuticals' higher probable upside, equities analysts clearly believe Jazz Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

In the previous week, Jazz Pharmaceuticals had 36 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 42 mentions for Jazz Pharmaceuticals and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.71 beat Jazz Pharmaceuticals' score of 0.35 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	11 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Jazz Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Summary

Jazz Pharmaceuticals beats Amneal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Neurocrine Biosciences has lower revenue, but higher earnings than Amneal Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.86	$72.06M	$0.49	35.80
Neurocrine Biosciences	$2.86B	5.47	$478.60M	$6.82	22.59

Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Amneal Pharmaceuticals presently has a consensus target price of $19.00, indicating a potential upside of 8.32%. Neurocrine Biosciences has a consensus target price of $200.86, indicating a potential upside of 30.38%. Given Neurocrine Biosciences' higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Neurocrine Biosciences has a net margin of 20.91% compared to Amneal Pharmaceuticals' net margin of 5.05%. Neurocrine Biosciences' return on equity of 22.43% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Neurocrine Biosciences	20.91%	22.43%	15.64%

In the previous week, Neurocrine Biosciences had 17 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 23 mentions for Neurocrine Biosciences and 6 mentions for Amneal Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 1.34 beat Amneal Pharmaceuticals' score of 0.71 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	20 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Amneal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Corcept Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.86	$72.06M	$0.49	35.80
Corcept Therapeutics	$761.41M	16.17	$99.65M	$0.42	271.14

Corcept Therapeutics has a net margin of 6.52% compared to Amneal Pharmaceuticals' net margin of 5.05%. Corcept Therapeutics' return on equity of 8.26% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Corcept Therapeutics	6.52%	8.26%	6.45%

In the previous week, Corcept Therapeutics had 18 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 24 mentions for Corcept Therapeutics and 6 mentions for Amneal Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.85 beat Amneal Pharmaceuticals' score of 0.71 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	17 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Amneal Pharmaceuticals currently has a consensus price target of $19.00, indicating a potential upside of 8.32%. Corcept Therapeutics has a consensus price target of $138.17, indicating a potential upside of 21.33%. Given Corcept Therapeutics' higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Corcept Therapeutics beats Amneal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Elanco Animal Health had 8 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Elanco Animal Health and 6 mentions for Amneal Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.36 beat Amneal Pharmaceuticals' score of 0.71 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 5.05% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Amneal Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$5.02B	2.40	-$232M	-$0.41	N/A
Amneal Pharmaceuticals	$3.02B	1.86	$72.06M	$0.49	35.80

Elanco Animal Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Elanco Animal Health presently has a consensus target price of $29.09, indicating a potential upside of 20.41%. Amneal Pharmaceuticals has a consensus target price of $19.00, indicating a potential upside of 8.32%. Given Elanco Animal Health's higher possible upside, research analysts clearly believe Elanco Animal Health is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Summary

Elanco Animal Health beats Amneal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRX vs. The Competition

Export

Metric	Amneal Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.60B	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	35.80	787.65	273.16	25.45
Price / Sales	1.86	792.39	592.64	73.57
Price / Cash	11.23	91.95	76.74	53.00
Price / Book	175.40	11.97	12.98	6.14
Net Income	$72.06M	$2.83B	$3.48B	$348.86M
7 Day Performance	-2.07%	0.39%	0.13%	-0.80%
1 Month Performance	-5.19%	5.34%	7.08%	4.13%
1 Year Performance	83.47%	6.05%	24.67%	15.17%

Amneal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRX Amneal Pharmaceuticals	3.4762 of 5 stars	$17.54 -2.6%	$19.00 +8.3%	+83.5%	$5.60B	$3.02B	35.80	8,500	Analyst Forecast
VTRS Viatris	2.7077 of 5 stars	$16.65 +0.6%	$17.50 +5.1%	+54.9%	$19.11B	$14.30B	N/A	30,000	Analyst Upgrade
JAZZ Jazz Pharmaceuticals	4.1514 of 5 stars	$259.80 +2.1%	$272.89 +5.0%	+91.4%	$16.82B	$4.60B	17.87	2,890	Trending News Analyst Forecast Analyst Revision
NBIX Neurocrine Biosciences	4.9549 of 5 stars	$153.06 +0.0%	$200.86 +31.2%	+10.4%	$15.55B	$3.37B	22.43	2,000	News Coverage Positive News Analyst Upgrade
CORT Corcept Therapeutics	4.0611 of 5 stars	$122.75 -0.4%	$138.17 +12.6%	+63.3%	$13.26B	$761.41M	292.05	300	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Amneal Pharmaceuticals compare to Viatris?

Summary

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Summary

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Summary

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, JAZZ, NBIX, CORT, and ELAN

How does Amneal Pharmaceuticals compare to Viatris?

Is AMRX or VTRS more profitable?

Does the media prefer AMRX or VTRS?

Do analysts rate AMRX or VTRS?

Which has higher earnings & valuation, AMRX or VTRS?

Do institutionals and insiders have more ownership in AMRX or VTRS?

Which has more volatility & risk, AMRX or VTRS?

Summary

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Which has better earnings & valuation, JAZZ or AMRX?

Do institutionals & insiders have more ownership in JAZZ or AMRX?

Is JAZZ or AMRX more profitable?

Do analysts rate JAZZ or AMRX?

Does the media refer more to JAZZ or AMRX?

Which has more risk and volatility, JAZZ or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Which has better valuation & earnings, AMRX or NBIX?

Which has more risk & volatility, AMRX or NBIX?

Do analysts recommend AMRX or NBIX?

Is AMRX or NBIX more profitable?

Does the media favor AMRX or NBIX?

Do institutionals and insiders believe in AMRX or NBIX?

Summary

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Which has higher earnings and valuation, AMRX or CORT?

Is AMRX or CORT more profitable?

Does the media favor AMRX or CORT?

Which has more volatility & risk, AMRX or CORT?

Do analysts recommend AMRX or CORT?

Do insiders and institutionals believe in AMRX or CORT?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Do institutionals & insiders believe in ELAN or AMRX?

Does the media favor ELAN or AMRX?

Is ELAN or AMRX more profitable?

Which has better valuation & earnings, ELAN or AMRX?

Which has more risk and volatility, ELAN or AMRX?

Do analysts recommend ELAN or AMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools